Drugs / GC203 TIL
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06828328 | Feb 2025 → Jan 2028 expected | pancreatic ductal adenocarcinoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT06488950 | Apr 2023 → Jun 2026 overdue | neoplasm | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT05468307 | Mar 2022 → Dec 2024 | female reproductive system neoplasm | Shanghai Juncell Therapeutics | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07256756 | Jan → Nov 2026 expected | — | Shanghai Juncell Therapeutics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-29 | Shanghai Juncell Therapeutics | Results 42天缩小40%，温和的GC203对肿瘤不温柔 juncell.com ↗
近日，君赛生物基因修饰型 TIL 疗法 GC203 在 I 期临床试验 (KUNLUN-001) 研究分中心重庆大学附属肿瘤医院完成首例受试者细胞回输后的首次肿瘤评估，患者肿瘤整体缩小约 40% ，达到部分缓解 (PR) 。 |
| 2024-10-30 | Shanghai Juncell Therapeutics | Results 更安全、更简便，GC203获临床亲历者好评 juncell.com ↗
在回输过程中，仅出现持续几小时的发热，对症处理后很快恢复；不良反应只有化验单上呈现的一过性血象降低，后自行恢复，出院时身体状态一切良好。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-29 | Shanghai Juncell Therapeutics | 42天缩小40%，温和的GC203对肿瘤不温柔 juncell.com ↗ |
| 2024-10-30 | Shanghai Juncell Therapeutics | 更安全、更简便，GC203获临床亲历者好评 juncell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC203 TIL | “This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.” NCT05468307 ↗ |
| Modality | Cell therapy | “Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient” NCT05468307 ↗ |
| Route | Intravenous | “i.v. infusion” NCT05468307 ↗ |